Natco launches new tumour drug

Hyderabad-based pharma firm, Natco Pharma has announced the launch of ibandronate sodium in tablet and injection forms.

Launched under the brand name of Bandrone, ibandronate sodium is used in the treatment of metastatic bone disease and elevated serum calcium levels in tumours. The company claims that it is superior to zoledronic acid, as use of ibandronate avoids monitoring of kidney function prior to each infusion and dose adjustments in patients with mild to moderate impairment.

This drug is priced at Rs 2,500 per 6 mg injection and Rs 49 per 50 mg tablet, as compared to the price of imported versions at Rs 13,500 per injection and Rs 600 per tablet, according to a statement from the company.